HOME ABOUT US PRINT PUBLICATIONS SUBSCRIPTIONS CONTACT US RSS
 
Subscriber Sign In
 
Today@FDA
FDA Calendar
 
Archived Daily Updates
 
FDA Whistleblower
 
What do you think?
Search our 64,388-story database
Search
Renew subscription










E-mail This to a Friend | Print Format  
     
 
Takeda Gains Expanded Approval for Gattex
05/17/2019
 

FDA has approved a Takeda Pharmaceuticals supplemental NDA to expand the indication for Gattex’s (teduglutide) for injection to pediatric patients aged one year and older with short bowel syndrome who need additional nutrition or fluids from intravenous feeding (parenteral support). Approval was based on data from a 24-week pediatric study that demonstrated Gattex helped reduce the volume of daily parenteral support (PS) required and time spent administering PS, the company says. “Some children even achieved complete freedom from PS,” it adds.

 

Takeda says Gattex has a demonstrated safety profile that is similar overall in pediatric and adult patients. The most common adverse reactions seen in adult patients are abdominal pain, nausea, upper respiratory tract infection, abdominal distension, injection site reaction, vomiting, fluid overload, and hypersensitivity, it says.


Post an instant comment on this report here

 
Any copying or electronic transfer without written permission is strictly prohibited and will result
in termination of service and prosecution under the federal Copyright Act.
To gain permission to copy this article log on to http://www.copyright.com.

FERDIC INCORPORATED - P.O. Box 28, Camp Hill, PA 17001 | Phone: (717)731-1426 fax:(717)731-1427 Email: info@fdaweb.com